Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...

Datroway demonstrated durable antitumor activity and an acceptable safety profile in advanced NSCLC with actionable genomic alterations, including EGFR and ALK subgroups.

The company states: “Datroway, or Dato-DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast ...

The US regulator has cleared TROP2-directed ADC datopotamab deruxtecan (Dato-DXd) under the Datroway trade name as a treatment for previously treated HR+/HER2- breast cancer, a few weeks after its ...

The FDA in January approved Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan (Datroway) for unresectable or metastatic, hormone receptor-positive, human epidermal growth factor receptor 2 ...

Daiichi Sankyo shares rose sharply after the U.S. Food and Drug Administration approved its breast cancer drug Datroway. Shares were recently 8.7% higher at 4,437 yen, equivalent to $28.39 ...

leading to three of the largest licensing deals in history along with the approvals of ENHERTU ® and DATROWAY ®, two precision cancer medicines invented with Daiichi Sankyo’s DXd ADC ...

Vandana Singh FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients AstraZeneca's Datroway gains FDA approval for HR-positive, HER2-negative breast cancer after prior therapies ...

First approval in the US for AstraZeneca and Daiichi Sankyo's Datroway based on TROPION-Breast01 results showing 37% reduction in the risk of disease progression or death vs. chemotherapy Datroway ...

Vandana Singh FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients AstraZeneca's Datroway gains FDA approval for HR-positive, HER2-negative breast cancer after prior therapies ...